DxS Licenses Scorpions Technology to Sangtec
By HospiMedica staff writers
Posted on 02 Mar 2004
A license agreement for technology leading to the development of in vitro diagnostic tests has been announced by DxS Ltd. (Manchester, UK) and Sangtec Molecular Diagnostics AB (SMD, Stockholm, Sweden). Posted on 02 Mar 2004
Under the terms of the agreement, SMD will gain access to the Scorpions technology of DxS to develop in vitro diagnostic kits. Scorpions is a fluorescence-based acid detection and genotyping system that provides an accurate, rapid, and reliable signal generation system with applications for genotyping, infectious disease testing, and RNA expression profiling.
"DxS' Scorpions technology offers reliable and highly sensitive DNA detection, key attributes that will support the development of our PCR-based tests as we look to extend the range of products within our core markets of oncology and infectious disease,” said Dr. Eva Pisa, CEO of SMD. "This is in line with our focus to develop and produce precise nucleic acid-based tests for the benefit of patients through improved diagnosis and tailoring of treatment regimens.” SMD is a fully owned subsidiary of Germany-based Altana Pharma AG.
Related Links:
DxS
SMD
Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
